EU Approves Sanofi and Regeneron's Dupixent for Severe Asthma

Date : 05/07/2019 @ 2:39PM
Source : Dow Jones News
Stock : Sanofi (SAN)
Quote : 81.41  -0.64 (-0.78%) @ 2:00AM
Sanofi share price Chart

EU Approves Sanofi and Regeneron's Dupixent for Severe Asthma

Sanofi (EU:SAN)
Historical Stock Chart

6 Months : From Apr 2019 to Oct 2019

Click Here for more Sanofi Charts.
   By Cristina Roca 

Sanofi SA (SAN.FR) and Regeneron Pharmaceuticals Inc. (REGN) said Tuesday that Dupixent has been approved for the treatment of severe asthma in the European Union.

The two pharmaceutical companies developed the drug jointly, they said in a press release.

Dupixent is approved in the EU to treat moderate-to-severe atopic dermatitis in adults, and has now been given approval by the European Commission to treat severe asthma with type 2 inflammation in adults and patients 12 years and older.


Write to Cristina Roca at; @_cristinaroca


(END) Dow Jones Newswires

May 07, 2019 09:24 ET (13:24 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191015 03:45:56